The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

Use of routine thoracentesis in addition to medical therapy yielded no significant benefits for adults with heart failure and ...

"Now, the WiSE System brings a leadless solution to left ventricular pacing ... SOLVE-CRT trial has delivered promising results for heart failure patients. The WiSE System offers hope to those ...

The following is a summary of "Novel Right Ventricular Function Parameters Can Identify Short-Term Non-Responders To ...

in heart failure (HF) patients with a left ventricular ejection fraction (LVEF) of ≥40% Additional data include a pooled analysis of the FINE-HEART trial, a causal mediation analysis of the ...

HFpEF is a type of heart failure in which the left ventricle becomes stiff and does not properly fill with blood, reducing the body's ability to effectively pump blood with each heartbeat.

The new technique uses a balloon and stent to clear blockages in LVADs. The National Heart Centre Singapore has introduced a ‘first-in-Singapore’ percutaneous procedure to treat complications in Left ...

achieving a statistically significant improvement in cardiovascular outcomes in heart failure patients with mildly reduced or preserved left ventricular ejection fraction (LVEF) of 40% or greater ...

CHICAGO -- For people with heart failure (HF), the long-presumed benefits ... Nearly 98% were white. Mean left ventricular ejection fraction was 40%; about half of the cohort had reduced ejection ...